Health Blueprint

Back to Longevity News

News summary

BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Source: GlobeNewswire - Biotech Financing • Published: 04 Nov 2026, 13:00

Summarized by Masters of Longevity from GlobeNewswire - Biotech Financing.

Company will sell shares and warrants to raise $4.74M.

BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Key Takeaways
  • BioVie is selling 2,962,500 shares at $1.60.
  • The offering is issuing warrants exercisable at $1.70.
  • Proceeds are intended for working capital and operations.
Read the full article at GlobeNewswire - Biotech Financing ↗

Continue exploring

Recommended MoL Picks

MoL PickFrom Metrics to Better LivingEverstride’s May 2026 Consumer Health Market Briefing shows a wellness market moving from products to systems, from tracking to guidance, and from optimization to meaning. The next winners in longevity may not be the companies that measure the most. They may be the ones that help consumers translate health data into a life they actually want to live.MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.MoL PickNucleotides and Longevity: Is the Evidence Ready?They help build DNA and keep cells working. Early human studies make nucleotide supplements interesting—but leave important questions about healthy ageing unanswered. Yet.